Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Study on B-cell receptors may help develop new treatment strategies for leukaemia

In order to track down pathogens and render them harmless, the immune system must be able to recognize myriad different foreign substances and react to them. Scientists at the Max Planck Institute of Immunobiology and the Centre for Biological Signalling Studies BIOSS at the University of Freiburg have discovered how the immune system's B-cells can be activated by numerous substances from our environment.

7 Oct 2010

Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

Biogen Idec today announced that more than 45 company and partner-sponsored platform and poster presentations will be presented during the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden, October 13 - 16, 2010.

6 Oct 2010

Seattle Genetics to present SGN-75 phase I data at ESMO Congress

Seattle Genetics, Inc. today announced that preliminary data from a phase I study of SGN-75 in relapsed and refractory non-Hodgkin lymphoma and metastatic renal cell carcinoma will be presented during a poster session at the 35th European Society for Medical Oncology (ESMO) Congress being held October 8-12, 2010 in Milan, Italy.

5 Oct 2010

Onconova announces agreement with FDA for Estybon- MDS Phase 3 trial

Onconova Therapeutics, Inc. announced agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase 3 trial for Estybon- (ON 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), diseases affecting the production of healthy blood cells in the bone marrow.

5 Oct 2010

Otsuka opens Canadian operations

Otsuka Canada Pharmaceutical Inc. has opened its first Canadian office, in the Montreal suburb of Saint-Laurent. This marks a major milestone in the continued growth of Otsuka in North America.

4 Oct 2010

Onconova enters agreement with FDA for Estybon Phase 3 trial SPA

Onconova Therapeutics®, Inc. announced agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase 3 trial for Estybon™ (ON 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), diseases affecting the production of healthy blood cells in the bone marrow.

4 Oct 2010

NIH to award $64M under Transformative Research Projects program

The National Institutes of Health will award up to $64 million over five years to encourage exploration of exceptionally innovative and original research ideas that have the potential for extraordinary impact.

4 Oct 2010

Researchers discover key leukemia defense mechanism

Virginia Commonwealth University Massey Cancer Center researcher Steven Grant, M.D., and a team of VCU Massey researchers have uncovered the mechanism by which leukemia cells trigger a protective response when exposed to a class of cancer-killing agents known as histone deacetylase inhibitors (HDACIs).

1 Oct 2010

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.

30 Sep 2010

Women's College to build Ontario's only ambulatory hospital focused on women's health

Women's College Hospital together with The Honourable Deb Matthews, Minister of Health and Long-Term Care, and women representing Ontario's diverse communities, today announced Women's College Hospital is building Ontario's only ambulatory hospital focused on meeting the unique health care needs and priorities of women.

30 Sep 2010

SCT transplantation benefits in Hodgkin's lymphoma is unclear

It remains an unresolved question whether adult patients with Hodgkin's lymphoma, a certain type of lymph node cancer, benefit from allogeneic stem cell transplantation (SCT) with an unrelated donor. This is due to the fact that studies are lacking that compare this therapy with autologous transplantation or conventional chemotherapy without SCT.

30 Sep 2010

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

ZymoGenetics, Inc. today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.

29 Sep 2010

Scientists develop NIA assay to determine drug's differential effects in tumor cells

A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work.We are making progress toward the goal of understanding how drugs work in different individuals, said Alice C. Fan, M.D., instructor in the division of oncology at Stanford University School of Medicine.

29 Sep 2010

Japanese Patent Office issues patent for ZIOPHARM Oncology's darinaparsin

ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.

28 Sep 2010

Takeda announces SGN-35 ADC trial results in Hodgkin lymphoma patients

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top line results from the pivotal trial of single agent brentuximab vedotin (SGN-35), an antibody drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.

27 Sep 2010

Researchers synthesize molecule to block abnormal protein in cancer cells

In the quest to arrest the growth and spread of tumors, there have been many attempts to get cancer genes to ignore their internal instruction manual. In a new study, a team led by Dana-Farber Cancer Institute scientists has created the first molecule able to prevent cancer genes from "hearing" those instructions, stifling the cancer process at its root.

27 Sep 2010

Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma

Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.

24 Sep 2010

Researchers discover new signaling pathway for cell development

Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia.

24 Sep 2010

U.S. House of Representatives declares September 2010 as 'Blood Cancer Awareness Month'

The U.S. House of Representatives today passed House Resolution 1433, declaring September 2010 as 'Blood Cancer Awareness Month.' The resolution helps raise awareness and support for issues affecting blood cancer patients within the halls of the Capitol.

24 Sep 2010

FDA grants ZIOPHARM's darinaparsin Orphan Drug Designation for peripheral T-cell Lymphoma treatment

ZIOPHARM Oncology, Inc. announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting fewer than 200,000 people in the United States.

23 Sep 2010

Lymphoma News and Research

Further Reading

Study on B-cell receptors may help develop new treatment strategies for leukaemia

Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

Seattle Genetics to present SGN-75 phase I data at ESMO Congress

Onconova announces agreement with FDA for Estybon- MDS Phase 3 trial

Otsuka opens Canadian operations

Onconova enters agreement with FDA for Estybon Phase 3 trial SPA

NIH to award $64M under Transformative Research Projects program

Researchers discover key leukemia defense mechanism

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Women's College to build Ontario's only ambulatory hospital focused on women's health

SCT transplantation benefits in Hodgkin's lymphoma is unclear

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

Scientists develop NIA assay to determine drug's differential effects in tumor cells

Japanese Patent Office issues patent for ZIOPHARM Oncology's darinaparsin

Takeda announces SGN-35 ADC trial results in Hodgkin lymphoma patients

Researchers synthesize molecule to block abnormal protein in cancer cells

Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma

Researchers discover new signaling pathway for cell development

U.S. House of Representatives declares September 2010 as 'Blood Cancer Awareness Month'

FDA grants ZIOPHARM's darinaparsin Orphan Drug Designation for peripheral T-cell Lymphoma treatment

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News